ArticleCureus2025
Characterization of Current Utilization of Machine Perfusion and Living-Donor Liver Transplantation for Hepatocellular Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients diagnosed with hepatocellular carcinoma (HCC) have experienced a decreased rate of deceased-donor transplants. We aimed to examine differences between two alternative approaches: living-donor liver transplantation (LDLT) and machine perfusion (MP). METHODOLOGY: Using national data, we identified 935 patients who underwent liver transplantation for a primary diagnosis of HCC between January 1, 2017, and December 31, 2023, using either MP or LDLT.
resultsA total of 537 patients were transplanted using MP compared with 398 with LDLT. Throughout the study period, patients transplanted using MP were more likely to be older (odds ratio (OR) 1.03,
conclusionsIncreased competition for organs after the implementation of acuity circle allocation has resulted in decreased rates of transplantation for HCC. LDLT has been one solution to increase access and remains a viable option for some patients. Conversely, MP may help centers offer organs to patients who are non-ideal living donor candidates without concern for worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.